Xeris Biopharma Reports Strong Q1 2026 Results, Swings to Profit, and Secures Key Patent Protection for Recorlev

summarizeSummary

Xeris Biopharma reported strong Q1 2026 results, achieving net income and positive operating cash flow, driven by significant Recorlev revenue growth and successful patent litigation to protect its market exclusivity.

check_boxKey Events

• Swing to Net Income

  The company reported net income of $2.2 million for Q1 2026, a significant improvement from a net loss of $9.2 million in Q1 2025.

• Strong Revenue Growth

  Total revenue increased by 38.3% to $83.1 million in Q1 2026 from $60.1 million in Q1 2025. Recorlev product revenue nearly doubled, growing 94.9% to $49.8 million.

• Positive Operating Cash Flow

  Net cash provided by operating activities was $9.9 million in Q1 2026, a substantial positive swing from $10.0 million used in operating activities in Q1 2025.

• Patent Protection for Recorlev

  The company filed patent infringement lawsuits against generic manufacturers for Recorlev, triggering a 30-month automatic stay on FDA approval for generic versions, extending market exclusivity until March 2040.

auto_awesomeAnalysis

Xeris Biopharma Holdings, Inc. delivered a robust first quarter, marking a significant turnaround to net income from a loss in the prior year. This positive financial performance was primarily driven by exceptional growth in Recorlev product revenue, which nearly doubled year-over-year. The company also achieved a critical milestone in protecting its key revenue driver by filing patent infringement lawsuits against generic manufacturers, triggering a 30-month stay on FDA generic approvals for Recorlev. This legal action provides extended market exclusivity, which is crucial for continued revenue growth and long-term stability. The company's operating activities generated positive cash flow, contributing to a stable cash position and reinforcing management's confidence in its liquidity for the next twelve months. While an existing ATM program provides future financing flexibility, no shares have been sold under it, indicating no immediate dilutive impact from this facility.